Cargando…
S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
Autores principales: | Marouf, Amira, Chaubard, Sammara, Michot, Jean Marie, Rossignol, Julien, Golfier, Camille, Allangba, Olivier, Philippe, Laure, Tessoulin, Benoit, Chauchet, Adrien, Deau, Bénédicte, Oberic, Lucie, Vargaftig, Jacques, Moignet, Aline, Clavert, Aline, Duléry, Rémy, Brisou, Gabriel, Tardy, Stéphanie, Fataccioli, Virginie, Houot, Roch, Olivier Casasnovas, Rene, Thieblemont, Catherine, Ghesquieres, Herve, Carras, Sylvain, Le Gouill, Steven, Cartron, Guillaume, Marabelle, Aurélien, Tournilhac, Olivier, Laurent Damaj, Gandhi, Gaulard, Philippe, Leval, Laurence De, Lemonnier, Francois, Bachy, Emmanuel, Hermine, Olivier, Couronné, Lucile, Jaccard, Arnaud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428228/ http://dx.doi.org/10.1097/01.HS9.0000967816.41118.bf |
Ejemplares similares
-
ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
por: Sibon, David, et al.
Publicado: (2022) -
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
por: Aubrais, Raphaelle, et al.
Publicado: (2022) -
S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
por: Houot, Roch, et al.
Publicado: (2023) -
Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
por: Cabannes‐Hamy, Aurélie, et al.
Publicado: (2018) -
P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)